Our early detection biomarker solution is built on precise, neurophysiologically informed markers that can be conveniently acquired from home or lean clinical settings using relatively inexpensive and portable technologies. Our patented technology allows us to detect those at high risk of developing Alzheimer’s disease 10-15 years before the first clinical symptoms become evident, that is, even before transitioning to mild cognitive impairment.
Early presymptomatic detection of Alzheimer's is within reach for everyone
Assessing Alzheimer's risk years before symptoms are evident
By creating the first decentralized platform based on our technology, we empower anyone across the globe to contribute to refining these early markers. Our inclusive model ensures that our database and marker reflect a diverse population, addressing equity and enhancing the universal applicability of our diagnostic tools.